Hematological toxicities in PARP inhibitors: A real‐world study using FDA adverse event reporting system (FAERS) database
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Medicine"
DOI: 10.1002/cam4.5062
Abstract: Poly ADP‐ribose polymerase inhibitors (PARPis) have significantly improved clinical effects in gynecological oncology. However, PARPis could also induce severe organ system toxicities, including the hematological system. Our study aimed to extensively characterize the hematological toxicities… read more here.
Keywords: hematological toxicities; system; toxicities parp; real world ... See more keywords
Safety and hematological toxicities of PARP inhibitors in patients with cancer: a systematic review of randomized controlled trials and a pharmacovigilance analysis
Sign Up to like & getrecommendations! Published in 2024 at "Expert Review of Anticancer Therapy"
DOI: 10.1080/14737140.2024.2357822
Abstract: ABSTRACT Introduction This study aimed to estimate the toxicities of PARP inhibitors (PARPis), based on randomized controlled trials (RCTs) and the FDA Adverse Event Reporting System (FAERS) database. Methods Four electronic databases were searched from… read more here.
Keywords: toxicities parp; controlled trials; hematological aes; randomized controlled ... See more keywords